Back to Directory

Rachel Scheckter

Email

rscheckter@fhi360.org

Phone

919-321-3540

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Ste. 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2050: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1

DAIDS Number

IMPAACT 2017: MOCHA

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1

DAIDS Number

Research Area

Study Status

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

Research Area

Study Status

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

Research Area

Study Status

Show All